Here is the design of a clinical trial:

Official Title: Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.

Included conditions:
- End-stage Renal Disease

Study Armgroups:
- {'label': 'Eplerenone group', 'type': 'EXPERIMENTAL', 'description': 'Eplerenone administration within 2 hours prior to patient departure to the operating room and for 4 days after kidney transplantation.', 'interventionNames': ['Drug: Eplerenone']}
- {'label': 'Placebo group', 'type': 'PLACEBO_COMPARATOR', 'description': 'Placebo administration within 2 hours prior to patient departure to the operatingroom and for 4 days after kidney transplantation', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Eplerenone', 'description': 'Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours', 'armGroupLabels': ['Eplerenone group']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Double-blinded Placebo administered for 4 days at 25mg every 12 hours', 'armGroupLabels': ['Placebo group']}

Primary Outcomes:
- {'measure': 'Iohexol clearance', 'description': 'Graft function at 3 months evaluated by GFR using iohexol clearance', 'timeFrame': '3 months'}

Please estimate the sample size based on the assumption: 
Standard deviation is 14 mL/min, significance level (alpha) is 5%, power (1-beta) is 80%, and a 5% dropout or non-randomization rate is anticipated.
Sample size and power calculation
          According to French statistical data (https://www.agence-biomedecine.fr/annexes/bilan2016/donnees/organes/06-rein/synthese.htm), the mean eGFR at 3Â months among patients receiving a kidney graft from an ECD is 42Â mL/min. Inclusion of 126 patients will allow identifying of a difference of 7Â mL/min/1.73Â m2 between the two groups (42Â mL/min/1.73Â m2 in the placebo group and 49Â mL/min/1.73Â m2 in the eplerenone group), with a standard deviation of 14Â mL/min, a two-sided alpha risk of 5%, and a beta risk of 20% (power 80%). Since it is anticipated that 5% of patients could be included but not randomized or could withdraw their consent, we will target the inclusion of 132 patients.